Christoph Berliner, Claudia Kesch, Wolfgang P Fendler, Matthias Eiber, Tobias Maurer
{"title":"[Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]","authors":"Christoph Berliner, Claudia Kesch, Wolfgang P Fendler, Matthias Eiber, Tobias Maurer","doi":"10.1007/s00120-022-01766-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation.</p><p><strong>Objectives: </strong>How and when is PSMA PET used in patient care to optimally direct therapy?</p><p><strong>Materials and methods: </strong>Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies.</p><p><strong>Conclusion: </strong>PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.</p>","PeriodicalId":11123,"journal":{"name":"Der Urologe. Ausg. A","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Der Urologe. Ausg. A","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-022-01766-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation.
Objectives: How and when is PSMA PET used in patient care to optimally direct therapy?
Materials and methods: Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies.
Conclusion: PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
